Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

Manon Buijs, Josephina A. Vossen, Jean Francois H. Geschwind, Takayoshi Ishimori, James M. Engles, Obele Acha-Ngwodo, Richard L. Wahl, Mustafa Vali

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. Materials and Methods: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later. Results: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p=0.002). FDG uptake did not significantly decrease in normal tissues after treatment. Conclusion: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.

Original languageEnglish (US)
Pages (from-to)120-123
Number of pages4
JournalInvestigational New Drugs
Volume27
Issue number2
DOIs
StatePublished - Apr 2009

Keywords

  • 3-Bromopyruvate
  • Animal model
  • Breast cancer
  • FDG
  • RMT

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer'. Together they form a unique fingerprint.

Cite this